Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Cancer Cell|August 20, 2021
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacyYujue Wang, Sixue Liu, Zhentao Yang, et al.
Nature Medicine|October 6, 2020
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trialAlain P Algazi, Megan Othus, Adil I Daud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204Raymond Y Huang, Gilbert Youssef, Thomas Nelson, et al.
Cancer|August 18, 2016
The efficacy of anti-PD-1 agents in acral and mucosal melanomaAlexander N Shoushtari, Rodrigo R Munhoz, Deborah Kuk, et al.
Immunity|December 16, 2018
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2018
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapyDan P Zandberg, Alain P Algazi, Antonio Jimeno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2020
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent MelanomaAlain P Algazi, Christopher G Twitty, Katy K Tsai, et al.
Cell|March 17, 2023
Dynamic CD8<sup>+</sup> T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodesMaha K Rahim, Trine Line H Okholm, Kyle B Jones, et al.
Neuro-Oncology|April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The Lancet. Oncology|November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 studyHussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
Pageof 5